| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Esophageal Neoplasms | 20 | 2012 | 3240 | 1.270 |
Why?
|
| Cyclin D1 | 6 | 2009 | 594 | 0.900 |
Why?
|
| NF-kappa B | 7 | 2009 | 1569 | 0.810 |
Why?
|
| Adenocarcinoma | 20 | 2013 | 7976 | 0.570 |
Why?
|
| Biomarkers, Tumor | 13 | 2015 | 10750 | 0.510 |
Why?
|
| Hedgehog Proteins | 7 | 2013 | 441 | 0.490 |
Why?
|
| Precancerous Conditions | 8 | 2009 | 1065 | 0.440 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 1559 | 0.360 |
Why?
|
| Gene Expression Profiling | 5 | 2015 | 5187 | 0.270 |
Why?
|
| Cyclooxygenase 2 | 1 | 2007 | 498 | 0.250 |
Why?
|
| Barrett Esophagus | 2 | 2008 | 561 | 0.240 |
Why?
|
| Carcinoma | 2 | 2006 | 2623 | 0.240 |
Why?
|
| Immunohistochemistry | 13 | 2013 | 7828 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 5 | 2011 | 4640 | 0.230 |
Why?
|
| Genomic Instability | 1 | 2007 | 523 | 0.230 |
Why?
|
| Laryngeal Neoplasms | 2 | 2009 | 533 | 0.220 |
Why?
|
| Chemoradiotherapy | 1 | 2011 | 2029 | 0.210 |
Why?
|
| Proto-Oncogene Proteins | 4 | 2014 | 2624 | 0.210 |
Why?
|
| Gene Expression Regulation, Neoplastic | 8 | 2012 | 9101 | 0.190 |
Why?
|
| Gene Amplification | 2 | 2005 | 770 | 0.180 |
Why?
|
| Mouth Neoplasms | 2 | 2003 | 734 | 0.170 |
Why?
|
| ras Proteins | 2 | 2014 | 802 | 0.170 |
Why?
|
| Genes, ras | 3 | 2008 | 681 | 0.170 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 8 | 2011 | 16612 | 0.160 |
Why?
|
| Bile Acids and Salts | 3 | 2013 | 261 | 0.160 |
Why?
|
| Lung Neoplasms | 6 | 2015 | 12012 | 0.160 |
Why?
|
| Fluorouracil | 5 | 2011 | 1988 | 0.160 |
Why?
|
| Stomach Neoplasms | 2 | 2007 | 2322 | 0.150 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2015 | 5566 | 0.150 |
Why?
|
| Carcinoma, Squamous Cell | 7 | 2009 | 5603 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 1998 | 263 | 0.140 |
Why?
|
| Disease Progression | 6 | 2007 | 6911 | 0.130 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2011 | 5421 | 0.120 |
Why?
|
| Combined Modality Therapy | 9 | 2009 | 9046 | 0.120 |
Why?
|
| Anus Neoplasms | 2 | 2009 | 417 | 0.120 |
Why?
|
| Vinblastine | 2 | 1994 | 462 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2015 | 5756 | 0.120 |
Why?
|
| Esophagectomy | 3 | 2008 | 947 | 0.120 |
Why?
|
| Humans | 46 | 2015 | 272087 | 0.120 |
Why?
|
| Disease-Free Survival | 4 | 2011 | 10259 | 0.110 |
Why?
|
| Aurora Kinases | 2 | 2011 | 194 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 5 | 2005 | 4138 | 0.110 |
Why?
|
| Colonic Neoplasms | 3 | 2013 | 1443 | 0.110 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2010 | 6270 | 0.110 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2014 | 131 | 0.110 |
Why?
|
| Aurora Kinase A | 2 | 2011 | 212 | 0.100 |
Why?
|
| Treatment Outcome | 10 | 2011 | 33909 | 0.100 |
Why?
|
| Protein Kinases | 2 | 2008 | 919 | 0.100 |
Why?
|
| Signal Transduction | 8 | 2013 | 12223 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2008 | 1905 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 341 | 0.100 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2012 | 135 | 0.100 |
Why?
|
| Cisplatin | 4 | 2011 | 2497 | 0.100 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2012 | 1575 | 0.100 |
Why?
|
| Colonic Polyps | 1 | 2013 | 221 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2013 | 399 | 0.090 |
Why?
|
| Prognosis | 8 | 2013 | 22555 | 0.090 |
Why?
|
| Sulfones | 2 | 2008 | 149 | 0.090 |
Why?
|
| Female | 22 | 2014 | 149288 | 0.090 |
Why?
|
| Antineoplastic Agents | 9 | 2010 | 14653 | 0.090 |
Why?
|
| Cell Communication | 1 | 2013 | 518 | 0.090 |
Why?
|
| Middle Aged | 16 | 2014 | 90460 | 0.090 |
Why?
|
| Colon | 1 | 2013 | 691 | 0.090 |
Why?
|
| Neoplasm Proteins | 3 | 2007 | 3363 | 0.080 |
Why?
|
| Ki-67 Antigen | 2 | 2009 | 685 | 0.080 |
Why?
|
| Disease Management | 1 | 2015 | 1113 | 0.080 |
Why?
|
| Lignans | 1 | 2009 | 14 | 0.080 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2013 | 642 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 4 | 2005 | 2319 | 0.080 |
Why?
|
| Male | 19 | 2014 | 129088 | 0.080 |
Why?
|
| Laryngeal Diseases | 1 | 2009 | 55 | 0.080 |
Why?
|
| Fenretinide | 1 | 2009 | 100 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2009 | 189 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 17 | 2 | 2009 | 668 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2009 | 196 | 0.080 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 1 | 2009 | 143 | 0.080 |
Why?
|
| Neoplasm Invasiveness | 2 | 2006 | 4071 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 1439 | 0.080 |
Why?
|
| Proteomics | 1 | 2015 | 1437 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2009 | 192 | 0.070 |
Why?
|
| Aged | 13 | 2011 | 73517 | 0.070 |
Why?
|
| alpha-Tocopherol | 2 | 2009 | 80 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2009 | 413 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2012 | 2085 | 0.070 |
Why?
|
| Isotretinoin | 2 | 2009 | 160 | 0.070 |
Why?
|
| Multigene Family | 2 | 2007 | 465 | 0.070 |
Why?
|
| Adult | 13 | 2014 | 81933 | 0.070 |
Why?
|
| Genetic Variation | 1 | 2015 | 2157 | 0.070 |
Why?
|
| Radiation Tolerance | 2 | 2008 | 636 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 1 | 2014 | 2576 | 0.070 |
Why?
|
| Guanine | 1 | 2007 | 157 | 0.070 |
Why?
|
| Risk Assessment | 3 | 2009 | 6885 | 0.070 |
Why?
|
| Drug Resistance, Multiple | 1 | 2007 | 221 | 0.070 |
Why?
|
| Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2006 | 74 | 0.070 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2006 | 58 | 0.070 |
Why?
|
| Genotype | 4 | 2010 | 4267 | 0.070 |
Why?
|
| Early Diagnosis | 1 | 2007 | 316 | 0.060 |
Why?
|
| Telomere | 1 | 2009 | 547 | 0.060 |
Why?
|
| Esophagus | 1 | 2009 | 564 | 0.060 |
Why?
|
| Chemoprevention | 1 | 2007 | 251 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2009 | 2139 | 0.060 |
Why?
|
| Neoplasm Staging | 4 | 2013 | 13993 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2007 | 615 | 0.060 |
Why?
|
| Metaplasia | 1 | 2007 | 387 | 0.060 |
Why?
|
| Infusions, Intravenous | 3 | 2006 | 1442 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 355 | 0.060 |
Why?
|
| Pharmaceutical Preparations | 1 | 2007 | 157 | 0.060 |
Why?
|
| Preoperative Care | 2 | 2008 | 1553 | 0.060 |
Why?
|
| Zinc Finger Protein GLI1 | 3 | 2012 | 115 | 0.060 |
Why?
|
| Esophagoscopy | 1 | 2007 | 310 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 887 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 3 | 2005 | 507 | 0.060 |
Why?
|
| Centrosome | 1 | 2005 | 107 | 0.060 |
Why?
|
| Injections, Intravenous | 1 | 2006 | 596 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2008 | 428 | 0.060 |
Why?
|
| Sirolimus | 2 | 2008 | 833 | 0.060 |
Why?
|
| Genomics | 1 | 2015 | 2830 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 4 | 2007 | 3512 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2008 | 5804 | 0.060 |
Why?
|
| Recurrence | 2 | 2011 | 4887 | 0.060 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 230 | 0.060 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2009 | 2472 | 0.060 |
Why?
|
| Pulmonary Alveoli | 1 | 2005 | 223 | 0.060 |
Why?
|
| Thymidylate Synthase | 2 | 2001 | 57 | 0.060 |
Why?
|
| Adenine | 1 | 2007 | 669 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2009 | 1014 | 0.060 |
Why?
|
| Membrane Proteins | 1 | 2014 | 2975 | 0.050 |
Why?
|
| Thyroid Neoplasms | 1 | 2014 | 1884 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2010 | 1011 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2014 | 5196 | 0.050 |
Why?
|
| Camptothecin | 1 | 2006 | 538 | 0.050 |
Why?
|
| Polymorphism, Single-Stranded Conformational | 1 | 2003 | 192 | 0.050 |
Why?
|
| Interferon-alpha | 2 | 2009 | 964 | 0.050 |
Why?
|
| Biopsy, Needle | 1 | 2007 | 1402 | 0.050 |
Why?
|
| Indoles | 1 | 2008 | 1034 | 0.050 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2009 | 1720 | 0.050 |
Why?
|
| Proportional Hazards Models | 2 | 2010 | 5118 | 0.050 |
Why?
|
| Taxoids | 1 | 2006 | 1010 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2013 | 5248 | 0.050 |
Why?
|
| RNA, Small Interfering | 4 | 2009 | 2219 | 0.050 |
Why?
|
| Cadherins | 1 | 2005 | 676 | 0.050 |
Why?
|
| Otorhinolaryngologic Neoplasms | 1 | 2001 | 22 | 0.050 |
Why?
|
| DNA Repair | 1 | 2009 | 1912 | 0.050 |
Why?
|
| Folic Acid Antagonists | 1 | 2001 | 48 | 0.050 |
Why?
|
| Genetic Markers | 2 | 2001 | 1077 | 0.050 |
Why?
|
| Radiotherapy | 4 | 2009 | 1860 | 0.040 |
Why?
|
| Cyclins | 1 | 2001 | 470 | 0.040 |
Why?
|
| Retrospective Studies | 5 | 2014 | 39831 | 0.040 |
Why?
|
| Neoplasm Metastasis | 2 | 2007 | 5330 | 0.040 |
Why?
|
| Fibroblast Growth Factor 3 | 1 | 1998 | 25 | 0.040 |
Why?
|
| Immunologic Factors | 1 | 2003 | 669 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2012 | 5506 | 0.040 |
Why?
|
| Cell Cycle Proteins | 2 | 2005 | 2129 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2006 | 3980 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2010 | 2446 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2008 | 9500 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 2496 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1998 | 190 | 0.040 |
Why?
|
| Cell Line, Tumor | 5 | 2013 | 14881 | 0.040 |
Why?
|
| Leukoplakia, Oral | 1 | 1997 | 71 | 0.040 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2014 | 1409 | 0.040 |
Why?
|
| Lung | 1 | 2008 | 3295 | 0.030 |
Why?
|
| Idoxuridine | 1 | 1996 | 17 | 0.030 |
Why?
|
| Immunoenzyme Techniques | 2 | 2009 | 1209 | 0.030 |
Why?
|
| Cluster Analysis | 2 | 2010 | 1074 | 0.030 |
Why?
|
| Mutation | 2 | 2014 | 15944 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2007 | 9326 | 0.030 |
Why?
|
| Blotting, Western | 3 | 2008 | 3646 | 0.030 |
Why?
|
| Transfection | 2 | 2013 | 3166 | 0.030 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2001 | 1351 | 0.030 |
Why?
|
| Iodine Radioisotopes | 1 | 1996 | 387 | 0.030 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1998 | 1132 | 0.030 |
Why?
|
| Mustard Compounds | 1 | 2013 | 9 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 3651 | 0.030 |
Why?
|
| Phenylpropionates | 1 | 2013 | 17 | 0.030 |
Why?
|
| Thyroid Nodule | 1 | 2014 | 94 | 0.030 |
Why?
|
| Chromosome Deletion | 1 | 1998 | 1056 | 0.030 |
Why?
|
| NIH 3T3 Cells | 1 | 2013 | 259 | 0.030 |
Why?
|
| Animals | 8 | 2013 | 62822 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2007 | 3929 | 0.030 |
Why?
|
| Cell Proliferation | 3 | 2012 | 7302 | 0.030 |
Why?
|
| Cell Hypoxia | 1 | 2013 | 353 | 0.030 |
Why?
|
| Phosphorylation | 2 | 2012 | 4984 | 0.020 |
Why?
|
| Mice | 6 | 2013 | 36053 | 0.020 |
Why?
|
| Vindesine | 1 | 1990 | 11 | 0.020 |
Why?
|
| Osteonectin | 1 | 2010 | 56 | 0.020 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2014 | 698 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2013 | 834 | 0.020 |
Why?
|
| Cell Division | 2 | 2008 | 2711 | 0.020 |
Why?
|
| Osteopontin | 1 | 2010 | 148 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2010 | 6236 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 473 | 0.020 |
Why?
|
| Cyclophilins | 1 | 2009 | 29 | 0.020 |
Why?
|
| Remission Induction | 3 | 2008 | 3645 | 0.020 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2005 | 4963 | 0.020 |
Why?
|
| Stromal Cells | 1 | 2013 | 835 | 0.020 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2009 | 74 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2013 | 1470 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 431 | 0.020 |
Why?
|
| DNA Methylation | 2 | 2013 | 2761 | 0.020 |
Why?
|
| Chenodeoxycholic Acid | 1 | 2008 | 23 | 0.020 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2008 | 55 | 0.020 |
Why?
|
| Anal Canal | 1 | 2009 | 238 | 0.020 |
Why?
|
| Endonucleases | 1 | 2009 | 184 | 0.020 |
Why?
|
| Apoptosis | 3 | 2008 | 7837 | 0.020 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2013 | 1004 | 0.020 |
Why?
|
| Prospective Studies | 1 | 2003 | 13410 | 0.020 |
Why?
|
| Neoplasms | 2 | 2007 | 15930 | 0.020 |
Why?
|
| 3' Untranslated Regions | 1 | 2009 | 339 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 461 | 0.020 |
Why?
|
| DNA Repair Enzymes | 1 | 2009 | 236 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 718 | 0.020 |
Why?
|
| BCG Vaccine | 1 | 2010 | 426 | 0.020 |
Why?
|
| Carcinogenesis | 1 | 2013 | 1037 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2009 | 661 | 0.020 |
Why?
|
| Trans-Activators | 2 | 2007 | 1660 | 0.020 |
Why?
|
| Reference Values | 1 | 2009 | 1155 | 0.020 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 1 | 2009 | 531 | 0.020 |
Why?
|
| Drug Therapy | 1 | 2007 | 206 | 0.020 |
Why?
|
| Mice, Nude | 2 | 2006 | 4360 | 0.020 |
Why?
|
| Chemokine CXCL2 | 1 | 2006 | 35 | 0.020 |
Why?
|
| Chemokine CXCL1 | 1 | 2006 | 68 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2008 | 760 | 0.020 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 129 | 0.020 |
Why?
|
| Radiotherapy Dosage | 2 | 2009 | 4003 | 0.020 |
Why?
|
| Informed Consent | 1 | 2009 | 415 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2008 | 1143 | 0.020 |
Why?
|
| Biological Transport | 1 | 2007 | 645 | 0.020 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 1992 | 1068 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2007 | 370 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2007 | 319 | 0.020 |
Why?
|
| Macrophages, Alveolar | 1 | 2005 | 71 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2005 | 123 | 0.020 |
Why?
|
| Chemokines | 1 | 2006 | 296 | 0.020 |
Why?
|
| Gastroesophageal Reflux | 1 | 2008 | 366 | 0.020 |
Why?
|
| Drug Administration Schedule | 3 | 1998 | 3543 | 0.010 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2005 | 202 | 0.010 |
Why?
|
| Endosonography | 1 | 2007 | 549 | 0.010 |
Why?
|
| Repressor Proteins | 1 | 2012 | 1730 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2005 | 300 | 0.010 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 15279 | 0.010 |
Why?
|
| Clinical Trials as Topic | 2 | 2006 | 3856 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2005 | 325 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 1057 | 0.010 |
Why?
|
| Hyperplasia | 1 | 2005 | 581 | 0.010 |
Why?
|
| Models, Biological | 1 | 2012 | 3223 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2010 | 4352 | 0.010 |
Why?
|
| Nitriles | 1 | 2008 | 945 | 0.010 |
Why?
|
| Hodgkin Disease | 1 | 1992 | 1488 | 0.010 |
Why?
|
| Rats | 1 | 2012 | 6640 | 0.010 |
Why?
|
| Base Sequence | 1 | 2009 | 5502 | 0.010 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2005 | 533 | 0.010 |
Why?
|
| RNA Interference | 1 | 2006 | 1397 | 0.010 |
Why?
|
| Cyclin D | 1 | 2001 | 40 | 0.010 |
Why?
|
| Epithelial Cells | 1 | 2009 | 1892 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2005 | 1832 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2007 | 2150 | 0.010 |
Why?
|
| DNA-Binding Proteins | 2 | 2009 | 5067 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2010 | 10365 | 0.010 |
Why?
|
| Paclitaxel | 1 | 2008 | 2099 | 0.010 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2001 | 233 | 0.010 |
Why?
|
| Chromosome Banding | 1 | 2001 | 280 | 0.010 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2005 | 3671 | 0.010 |
Why?
|
| Gene Expression | 1 | 2009 | 3690 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2001 | 297 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 1996 | 3704 | 0.010 |
Why?
|
| Adenoma | 1 | 2005 | 745 | 0.010 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1049 | 0.010 |
Why?
|
| Loss of Heterozygosity | 1 | 2001 | 626 | 0.010 |
Why?
|
| Microsatellite Repeats | 1 | 2001 | 629 | 0.010 |
Why?
|
| Aneuploidy | 1 | 2001 | 377 | 0.010 |
Why?
|
| Karyotyping | 1 | 2001 | 1064 | 0.010 |
Why?
|
| Anticarcinogenic Agents | 1 | 2001 | 372 | 0.010 |
Why?
|
| Liver Neoplasms | 1 | 1996 | 4811 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 1994 | 16244 | 0.010 |
Why?
|
| Survival Rate | 2 | 2008 | 12534 | 0.010 |
Why?
|
| DCC Receptor | 1 | 1998 | 13 | 0.010 |
Why?
|
| Risk Factors | 2 | 2009 | 18051 | 0.010 |
Why?
|
| Phosphoribosyl Pyrophosphate | 1 | 1998 | 7 | 0.010 |
Why?
|
| Neutropenia | 2 | 1994 | 1001 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2008 | 5841 | 0.010 |
Why?
|
| Inflammation | 1 | 2008 | 2535 | 0.010 |
Why?
|
| Laparoscopy | 1 | 2007 | 1298 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 1998 | 5107 | 0.010 |
Why?
|
| Smad2 Protein | 1 | 1998 | 92 | 0.010 |
Why?
|
| Kinetics | 1 | 2001 | 2242 | 0.010 |
Why?
|
| Nucleotides | 1 | 1998 | 175 | 0.010 |
Why?
|
| Thiophenes | 1 | 1998 | 148 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 2841 | 0.010 |
Why?
|
| Smad4 Protein | 1 | 1998 | 202 | 0.010 |
Why?
|
| Injections, Intra-Arterial | 1 | 1996 | 55 | 0.010 |
Why?
|
| Ovarian Neoplasms | 1 | 1992 | 4797 | 0.010 |
Why?
|
| Cell Death | 1 | 1998 | 689 | 0.010 |
Why?
|
| RNA, Neoplasm | 1 | 1998 | 810 | 0.010 |
Why?
|
| Cell Adhesion Molecules | 1 | 1998 | 582 | 0.010 |
Why?
|
| Hepatic Artery | 1 | 1996 | 257 | 0.010 |
Why?
|
| Radionuclide Imaging | 1 | 1996 | 656 | 0.010 |
Why?
|
| Metabolic Clearance Rate | 1 | 1994 | 241 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1998 | 1364 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1998 | 911 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1998 | 1650 | 0.010 |
Why?
|
| Point Mutation | 1 | 1997 | 793 | 0.010 |
Why?
|
| Chromosome Aberrations | 1 | 2001 | 2035 | 0.010 |
Why?
|
| HeLa Cells | 1 | 1997 | 1718 | 0.010 |
Why?
|
| DNA | 1 | 2001 | 3089 | 0.010 |
Why?
|
| Quinazolines | 1 | 1998 | 953 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 1997 | 1972 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 13139 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2001 | 4200 | 0.010 |
Why?
|
| Drug Evaluation | 1 | 1990 | 435 | 0.010 |
Why?
|
| Radiometry | 1 | 1996 | 1017 | 0.010 |
Why?
|
| Biopsy | 1 | 1997 | 3544 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1990 | 738 | 0.010 |
Why?
|
| Bone Marrow | 1 | 1996 | 2446 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1990 | 507 | 0.000 |
Why?
|
| Liver | 1 | 1996 | 3123 | 0.000 |
Why?
|